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Abstract
Detailed structure^activity investigations aimed at probing the anchor chain length dependency for glycerol-based
lipofectins have been reported previously. Herein, we report on the first detailed investigation on the anchor-dependent
transfection biology of non-glycerol based simple monocationic cytofectins containing single 2-hydroxyethyl head group
functionality using 11 new structural analogs of our previously published first generation of non-glycerol based transfection
lipids (lipids 1^11). The C-14 and C-16 analogs of DOMHAC (lipids 4 and 5, respectively) were found to be remarkably
efficient in transfecting COS-1 cells. In addition, the present anchor-dependency investigation also revealed that the C-14
analog of DOHEMAB (lipid 10) is significantly efficient in transfecting both COS-1 and NIH3T3 cells. Our results also
indicate that too strong lipid^DNA interactions might result in weaker transfection for non-glycerol based cationic lipids. In
summary, the anchor-dependence investigations presented here convincingly demonstrate that non-glycerol based cationic
lipids containing a single hydroxyethyl head group and hydrophobic C-14 or C-16 anchors are promising non-toxic cationic
transfection lipids for future use in liposomal gene delivery. ß 2002 Published by Elsevier Science B.V.
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(tetradecanoyloxy)propyl]ammonium chloride; DMRIE, 1,2-dimyristyloxypropyl-3-dimethyl-hydroethyl ammonium bromide; DOTAP,
1,2-dioleoyloxy-3-(trimethylamino)propane; DOPE, 1,2-dioleoyl-propyl-3-phosphatidylethanolamine; DOMHAC, N,N-di-n-octadecyl-N-
methyl,N-(2-hydroxyethyl)ammonium chloride; DCMHAC, N,N-di-n-capryl-N-methyl,N-(2-hydroxyethyl)ammonium chloride;
DDMHAC, N,N-di-n-decyl-N-methyl,N-(2-hydroxyethyl)ammonium chloride; DLMHAC, N,N-di-n-lauryl-N-methyl,N-(2-hydroxyethyl)-
ammonium chloride; DMMHAC, N,N-di-n-myristyl-N-methyl,N-(2-hydroxyethyl)ammonium chloride; DHMHAC, N,N-di-n-hexadecyl-
N-methyl,N-(2-hydroxyethyl)ammonium chloride; DOHEMAB, N,N-di[O-hexadecanoyl]hydroxyethyl-N-hydroxyethyl-N-methylammo-
nium bromide; DCHEMAB, N,N-di[O-caproyl]hydroxyethyl-N-hydroxyethyl-N-methylammonium bromide; DDHEMAB, N,N-di[O-dec-
anoyl]hydroxyethyl-N-hydroxyethyl-N-methylammonium bromide; DLHEMAB, N,N-di[O-lauroyl]hydroxyethyl-N-hydroxyethyl-N-
methylammonium bromide; DMHEMAB, N,N-di[O-myristoyl]hydroxyethyl-N-hydroxyethyl-N-methylammonium bromide; MOOHAC,
N-methyl-N-n-octadecyl-N-oleyl-N-hydroxyethylammonium chloride
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1. Introduction
Synthetic DNA delivery agents are gaining increas-
ing importance in gene therapy as an alternative to
viral vectors [1]. Robust manufacture, simplicity of
handling techniques, low immunogenic response, and
ability to form stable injectable complexes even with
large DNA associated with cationic lipid mediated
gene delivery are increasingly making them the vec-
tors of choice among the arsenal of non-viral trans-
fection vectors currently in use [2^10], ([11] and refer-
ences therein), [12^31]. The term ‘cytofectins’
speci¢es this class of positively charged lipid mole-
cules that can facilitate the functional entry of poly-
nucleotides, macromolecules, and small molecules
into living cells. Molecular architectures of cationic
transfection lipids are, in general, composed of three
segments namely, a hydrophobic anchor, a linker,
and a head group. The contribution of each of these
segments on the overall transfection is inadequately
understood. Based on several studies it is apparent
that the physical properties of the lipid^DNA com-
plex, viz. size, surface charge and accessibility of the
DNA in a complex have strong bearing on the trans-
fection e⁄ciency. Mapping transfection e⁄ciency
onto various segments of the cationic lipids is a chal-
lenging exercise.
A plethora of newer and more e⁄cient cationic
transfection lipids have been reported following the
pioneering development of the glycerol based cation-
ic lipid DOTMA [1] by Felgner et al. in 1987. Inter-
estingly, the glycerol linker between the cationic head
groups and the hydrophobic tails were retained in
the molecular design of many of these subsequently
developed transfection lipids such as, DOTAP [31],
DMDHP [18], DMRIE [8], etc. Recently, we re-
ported four e⁄cient non-glycerol based non-toxic
monocationic transfection lipids namely, DHDEAB,
MOOHAC, DOMHAC and DOHEMAB [13], in
which aliphatic hydrocarbon tails containing 16 or
more carbon atoms were covalently linked to the
cationic head groups either directly or via an ester
group linker. Out of these four non-glycerol based
lipids DHDEAB, the most e⁄cient one, contains two
2-hydroxyethyl and two n-dexadecyl aliphatic hydro-
carbon tails directly attached to the quaternized ni-
trogen atom. The in vitro transfection e⁄ciency of
DHDEAB in COS-1 cells was found to be 2^3-fold
better than that of lipofectamine, one of the most
extensively used commercially available transfection
lipids. The remaining three transfection lipids of less-
er transfection e⁄ciency namely, MOOHAC, DOM-
HAC and DOHEMAB, contained only one 2-hy-
droxyethyl head group functionality covalently
attached to the positively charged nitrogen atom.
Detailed structure^activity investigations aimed at
probing the anchor chain length dependency for
glycerol-based lipofectins have been reported [6^
8,18]. Herein, we report on the ¢rst detailed investi-
gation on the anchor-dependent transfection biology
of non-glycerol based simple monocationic cytofec-
tins containing single 2-hydroxyethyl head group
functionality using six new DOMHAC (lipids 1^6,
Chart 1) and ¢ve new DOHEMAB (lipids 7^11,
Chart 1) structural analogs. As delineated below,
the C-14 and C-16 analogs of DOMHAC (lipids 4
and 5, respectively, Chart 1) were found to be re-
markably e⁄cient in transfecting COS-1 cells. In ad-
dition, the present anchor-dependency investigation
also revealed that the C-14 analog of DOHEMAB
(lipid 10, Chart 1) is signi¢cantly e⁄cient in trans-
fecting COS-1 and NIH3T3 (a hard-to-transfect pri-
mary cell line) cells. Our results also indicate that too
strong lipid^DNA interactions might result in weak-
er transfection for non-glycerol based cationic lipids.
In summary, the anchor-dependence investigations
delineated in this paper convincingly demonstrate
that non-glycerol based cationic lipids containing a
single hydroxyethyl head group and hydrophobic
C-14 or C-16 anchors are promising non-toxic
cationic transfection lipids for future use in non-viral
gene therapy.
2. Materials and methods
2.1. Materials
pCMV.SPORT-L-gal, cell culture media and fetal
calf serum were purchased from Gibco BRL, Rock-
ville, MD, USA. NP-40, ethidium bromide, antibiot-
ics, agarose, o-nitrophenyl-L-D-galactopyranoside
were purchased from Sigma, St. Louis, MO, USA.
DNA molecular mass markers were purchased from
Bangalore Genei, Bangalore, India. Cholesterol was
purchased from Avanti Polar, AL, USA. COS-1 cell
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line (SV 40 transformed African green monkey kid-
ney, #ATCC CRL 1650) was obtained from ATCC,
MD, USA. Unless otherwise stated, all reagents were
of analytical grade purchased from local commercial
suppliers and were used without further puri¢cation.
Column chromatography was performed with silica
gel (Acme Synthetic Chemicals, India, ¢ner than 200
and 60^120 mesh).
2.2. Syntheses
Lipids 1^5 were synthesized following our previ-
ously published protocol [13] for the synthesis of
DOMHAC (lipid 6, Chart 1).
1H-NMR (200 MHz, CDCl3) of lipids 1--5 :
DCMHAC (1) N/ppm = 0.90 [t, 6H, CH3-(CH2)5-] ;
1.20^1.40 [m, 20H, -(CH2)5-] ; 1.60^1.75 [br, 4H,
CH3(HOCH2-CH2)N(CH2-CH2-)2] ; 3.35 [s, 3H,
CH3(HOCH2-CH2)N(CH2-CH2-)2] ; 3.40^3.58 [br,
2H, CH3(HO-CH2-CH2)N(CH2-CH2-)2-] ; 3.70^
3.78 [br, 2H, CH3 (HO-CH2-CH2)2N(CH2-
CH2-)2] ; 4.07^4.13 [br, 2H, CH3(HO-CH2-CH2)-
N(CH2-CH2-)2].
DDMHAC (2) N/ppm = 0.80^0.90 [t, 6H, CH3-
(CH2)7-] ; 1.15^1.45 [m, 28H, -(CH2)7-] ; 1.60^1.80
[br, 4H, CH3(HOCH2-CH2)N(CH2-CH2-)2] ; 3.35
[s, 3H, CH3(HOCH2-CH2)N(CH2-CH2-)2] ; 3.40^
3.55 [br, 2H, CH3(HO-CH2-CH2)N(CH2-CH2-)2-] ;
3.65^3.78 [br, 2H, CH3 (HO-CH2-CH2)2N(CH2-
CH2-)2] ; 4.00^4.13 [br, 2H, CH3(HO-CH2-CH2)-
N(CH2-CH2-)2].
DLMHAC (3) N/ppm = 0.81^0.97 [t, 6H, CH3-
(CH2)9-] ; 1.20^1.45 [m, 36H, -(CH2)9-] ; 1.60^1.80
[br, 4H, CH3(HOCH2-CH2)N(CH2-CH2-)2] ; 3.35
[s, 3H, CH3(HOCH2-CH2)N(CH2-CH2-)2] ; 3.41^
3.58 [br, 2H, CH3(HO-CH2-CH2)N(CH2-CH2-)2-] ;
3.68^3.78 [br, 2H, CH3 (HO-CH2-CH2)2N(CH2-
CH2-)2] ; 4.05^4.17 [br, 2H, CH3(HO-CH2-CH2)N-
(CH2-CH2-)2].
DMMHAC (4) N/ppm = 0.90 [t, 6H, CH3-(CH2)11-] ;
1.20^1.45 [m, 44H, -(CH2)11-] ; 1.60^1.80 [br, 4H,
CH3(HOCH2-CH2)N(CH2-CH2-)2] ; 3.35 [s, 3H,
CH3(HOCH2-CH2)N(CH2-CH2-)2] ; 3.41^3.58 [br,
2H, CH3(HO-CH2-CH2)N(CH2-CH2-)2-] ; 3.70^
3.80 [br, 2H, CH3 (HO-CH2-CH2)2N(CH2-CH2-)2] ;
4.07^4.13 [br, 2H, CH3(HO-CH2-CH2)N(CH2-
CH2-)2].
DHMHAC (5) N/ppm = 0.90 [t, 6H, CH3-(CH2)13-] ;
1.20^1.45 [m, 52H, -(CH2)13-] ; 1.60^1.80 [br, 4H,
CH3(HOCH2-CH2)N(CH2-CH2-)2] ; 3.35 [s, 3H,
CH3(HOCH2-CH2)N(CH2-CH2-)2] ; 3.41^3.58 [br,
2H, CH3(HO-CH2-CH2)N(CH2-CH2-)2-] ; 3.70^
3.80 [br, 2H, CH3 (HO-CH2-CH2)2N(CH2-CH2-)2] ;
4.07^4.13 [br, 2H, CH3(HO-CH2-CH2)N(CH2-
CH2-)2].
Lipids 7^10 were synthesized following our previ-
ously published protocol [13] for the synthesis of
DOHEMAB (lipid 11, Chart 1).
1H-NMR (200 MHz, CDCl3) of lipids 7-10 :
DCHEMAB (7) N/ppm = 0.88 [t, 6H, CH3-(CH2)4] ;
1.20^1.40 [m, 16H, -(CH2)4-] ; 1.50^1.70 [m,
4H, CH3(HOCH2-CH2)N(CH2-CH2-O-CO-CH2-
CH2-)2] ; 2.22^2.40 [t, 4H, CH3(HOCH2-CH2)N-
(CH2-CH2-O-CO-CH2-CH2-)2] ; 3.43 [S, 3H, CH3-
(HOCH2-CH2)N(CH2-CH2-O-CO-CH2-CH2-)2] ;
Chart 1. DOMHAC and DOHEMAB analogs used in the
study.
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3.90^4.22 [m, 9H, CH3(HOCH2-CH2)N(CH2-CH2-
O-CO-CH2-CH2-)2] ; 4.58^4.65 [br, t, 4H, CH3-
(HOCH2-CH2)N(CH2-CH2-O-CO-CH2-CH2-)2].
DDHEMAB (8) N/ppm = 0.88 [t, 6H, CH3-(CH2)6 ] ;
1.20^1.42 [m, 24H, -(CH2)6-] ; 1.50^1.75 [m,
4H, CH3(HOCH2-CH2)N(CH2-CH2-O-CO-CH2-
CH2-)2] ; 2.22^2.40 [2t, 4H, CH3(HOCH2-CH2)N-
(CH2-CH2-O-CO-CH2-CH2-)2] ; 3.43 [S, 3H, CH3-
(-HOCH2-CH2)N(CH2-CH2-O-CO-CH2-CH2-)2] ;
3.90^4.20 [m, 9H, CH3(HOCH2-CH2)N(CH2-CH2-
O-CO-CH2-CH2-)2] ; 4.55^4.65 [br, t, 4H, CH3-
(HOCH2-CH2)N(CH2-CH2-O-CO-CH2-CH2-)2].
DLHEMAB (9) N/ppm = 0.88 [t, 6H, CH3-(CH2)8] ;
1.20^1.40 [m, 32H, -(CH2)8-] ; 1.50^1.65 [m,
4H, CH3(HOCH2-CH2)N(CH2-CH2-O-CO-CH2-
CH2-)2] ; 2.25^2.42 [2t, 4H, CH3(HOCH2-CH2)N-
(CH2-CH2-O-CO-CH2-CH2-)2] ; 3.45 [S, 3H, CH3-
(HOCH2-CH2)N(CH2-CH2-O-CO-CH2-CH2-)2] ;
3.82^4.35 [m, 9H, CH3(HOCH2-CH2)N(CH2-CH2-
O-CO-CH2-CH2-)2] ; 4.48^4.68 [br, t, 4H, CH3-
(HOCH2-CH2)N(CH2-CH2-O-CO-CH2-CH2-)2].
DMHEMAB (10) N/ppm = 0.88 [t, 6H, CH3-
(CH2)10-] ; 1.20^1.40 [m, 40H, -(CH2)10-] ; 1.50^1.65
[m, 4H, CH3(HOCH2-CH2)N(CH2-CH2-O-CO-
CH2-CH2-)2] ; 2.25^2.40 [2t, 4H, CH3(HOCH2-
CH2)N(CH2-CH2-O-CO-CH2-CH2-)2] ; 3.43 [S,
3H, CH3(HOCH2-CH2)N(CH2-CH2-O-CO-CH2-
CH2-)2] ; 3.85^4.20 [m, 9H, CH3(HOCH2-CH2)N-
(CH2-CH2-O-CO-CH2-CH2-)2] ; 4.55^4.62 [br, t,
4H, CH3(HOCH2-CH2)N(CH2-CH2-O-CO-CH2-
CH2-)2].
2.3. Liposome preparation
The mixtures of cationic amphiphiles and the col-
ipid (cholesterol) in the appropriate ratios were dis-
solved in chloroform in a glass vial. The chloroform
was removed with a thin £ow of moisture free nitro-
gen and the dried ¢lm of lipid left in the vial was
then kept under high vacuum for 8 h. One ml of
autoclaved sterile deionized water was added to the
vacuum dried lipid ¢lm and the mixture was allowed
to swell for 15 h (overnight). The vial was then vor-
texed for 2^3 min at room temperature and occasion-
ally shaken in 45‡C water bath to produce multila-
mellar vesicles (MLV). Small unilamellar vesicles
(SUV) were then prepared by sonicating the MLV
placed in an ice bath for 3^4 min until clarity using a
Branson 450 soni¢er at 100% duty cycle and 25 W
output power.
2.4. Preparation of plasmid DNA
pCMV.SPORT-L-gal plasmid DNA was prepared
by alkaline lysis procedure and puri¢ed by PEG-8000
precipitation according to Maniatis and coworkers
[32]. The plasmid preparations showing OD260/
OD280 more than 1.8 were used.
2.5. Transfection assays
COS-1 and NIH3T3 cells were seeded at a density
of 15 000 cells/well in a 96-well plate 18 h before the
transfection. Plasmid (0.15 Wg) was complexed with
varying amounts of lipid (0.05^4.3 nmol) in 13 Wl of
plain DMEM medium for 30 min. The charge ratios
were varied from 0.1:1 to 9:1 ( þ ) over this range of
the lipid. The complex was diluted to 100 Wl with
plain DMEM and added to the wells. After 3 h of
incubation, 100 Wl of DMEM with 10% FCS was
added to the cells. The medium was changed to
10% complete medium after 24 h and the reporter
gene activity was estimated after 48 h. The cells
were washed twice with PBS and lysed in 50 Wl
of lysis bu¡er (0.25 M Tris^HCl (pH 8.0) and 0.5%
NP40). Care was taken to ensure complete lysis. The
L-galactosidase activity per well was estimated by
adding 50 Wl of 2U substrate solution (1.33 mg/ml
of ONPG, 0.2 M sodium phosphate (pH 7.15)
and 2 mM magnesium chloride) to the lysate in a
96-well plate. Absorption at 405 nm was converted
to L-galactosidase units by using calibration curve
constructed with pure commercial L-galactosidase
enzyme. The values of L-galactosidase units in repli-
cate plates assayed on the same day varied by less
than 30%. The transfection e⁄ciency values reported
were average values from four replicate transfection
plates assayed on the same day. Each transfection
experiment was repeated three times on three di¡er-
ent days and the day-to-day variation in average
transfection e⁄ciency values for identically treated
replicate transfection plates was 2^3-fold and was
dependent on the cell density and conditions of the
cells.
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2.6. Exclusion of ethidium bromide (EtBr) from DNA
by the cationic lipids
The extent of EtBr binding to the DNA was moni-
tored by the changes in the £uorescence. EtBr £uo-
rescence was monitored in Hitachi 4500 £uorimeter
by setting the excitation wavelength at 518 nm and
emission wavelength at 585 nm. To one ml of TE
bu¡er (pH 8.0), 0.78 nmol of DNA and 2.5 nmol
of EtBr were added. The change in £uorescence
was monitored after adding small volumes of lipids
1^6 to the EtBr:DNA complex. Arbitrary £uores-
cence values were recorded after allowing su⁄cient
time for equilibration. The order of addition of EtBr
or lipid to DNA did not alter the ¢nal values, indi-
cating that the equilibrium does not depend on the
order of addition and reaches in minutes. Percent
£uorescence was calculated considering the £uores-
cence value in the absence of lipid as 100.
2.7. Toxicity assay
Cytotoxic e¡ects of the lipoplexes made from lip-
ids 1^11 were tested on COS-1 cell lines using the
MTT assay as described previously [13]. The treat-
ment protocols were identical for both cytotoxicity
and transfection assays.
3. Results and discussion
3.1. Transfection biology for lipids 1^6
The transfection e⁄ciencies of the cationic lipids
1^6 were tested using the pCMV-L-gal plasmid car-
rying the L-galactosidase reporter gene. Since cation-
ic transfection lipids work e⁄ciently with colipids,
preferably DOPE or cholesterol, we initially tested
the transfection e⁄ciencies of the lipid formulations
containing the cationic lipids 1^6 using both choles-
terol and DOPE as colipids at 1:1 mole ratios, and
lipids 1^6 showed remarkably higher reporter gene
activity with cholesterol as colipid compared to
DOPE (data not shown). Lipid/DNA charge ratios
between 1 and 3 produced maximal reporter gene
activity (Fig. 1A,B). Above 3:1 charge ratio and up
to 9:1, the transfection e⁄ciency was poor as seen by
the decrease in L-gal activity (Fig. 1A,B). In the
present study we have compared the transfection ef-
¢ciencies of the six lipids 1^6 with that of lipofect-
amine, one of the most widely used commercially
available cationic transfection lipids. In COS-1 cells
lipids 4^6 gave transfection comparable to lipofect-
amine (Fig. 1A). Lipid 5 containing C-16 hydropho-
bic chains was better among the monohydroxyethyl
head group containing compounds, while lipids 1^3
Fig. 1. Transfection e⁄ciencies of lipids 1^6 in COS-1 cells (A) and in NIH3T3 cells (B) using cholesterol as the colipid (at 1:1 mole
ratio of lipid to cholesterol). The transfection e⁄ciencies of the lipids 1 (a), 2 (b), 3 (E), 4 (F), 5 (O) and 6 (R) were compared with
that of lipofectamine (P). Units of L-galactosidase activity were plotted against the varying lipid to DNA ( þ ) charge ratios. The o-ni-
trophenol formation (Wmol of o-nitrophenol produced/min) was converted to units using standard curve obtained with pure (commer-
cial) L-galactosidase. All lipids were tested on the same day and the data presented are an average of three experiments (n = 3). DNA
(0.3 Wg) was complexed with lipid at various charge ratios in a volume of 50 Wl for 30 min and added to cells after diluting the me-
dium to 100 Wl. The incubation of lipoplex with cells was allowed for 30 min before adding another 100 Wl of DMEM medium. The
reporter gene activity was assayed after 48 h by lysing the cells with NP40 (0.5%) containing PBS.
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did not show any transfection, indicating that mini-
mum 14-carbon anchor length is essential for impart-
ing transfection properties to our novel mono-hy-
droxyethyl head group containing monocationic
lipids (Fig. 1A).
In general, the presence of membrane reorganizing
unsaturated hydrophobic alkenyl chains in the mo-
lecular architecture of cationic lipids is known to
enhance their transfection e⁄ciencies. However, in
COS-1 cells, lipids 4^6 with no unsaturated anchors
and MOOHAC, an unsaturated alkenyl anchor con-
taining monocationic transfection lipid with a single
hydroxyethyl head group previously reported by us
[13], were found to be equally transfection e⁄cient
(Fig. 1A). Such superior transfection properties of
myristyl analogs compared to palmitoyl, stearyl and
oleyl derivatives have also been previously reported
for cationic transfection lipids with di¡erent head
groups [15,19,28].
Interestingly, unlike in COS-1 cells, lipid 4 was
observed to be the only lipid that showed signi¢cant
(better than lipofectamine) transfection properties in
NIH3T3 cells (Fig. 1B). The cell biological basis of
higher transfection by lipid 4 in NIH3T3 cells is not
clear. Whether or not the signi¢cant transfection
property of lipid 4 has any bearing with the e⁄cient
cellular uptake of the relevant lipoplexes is still an
open question. Very recently, we have observed that
lipid 4 is also remarkably e⁄cient in transfecting
HepG2 cells (G.V. Srilakshmi et al., unpublished re-
sults). Since, in principle, ligands speci¢c to liver cell
receptors can be covalently tagged to the surface of
lipid 4, such a surface-modi¢ed lipid 4 is likely to
¢nd future applications as an e⁄cient transfection
vector in targeted gene therapy of liver cancer.
3.2. Transfection biology for lipids 7^11
The conformational £exibility/rigidity of a trans-
fection lipid as well as optimal contact between the
cationic head group and the negatively charged phos-
phate of the DNA in lipoplexes are likely to be
modulated by the linker functionality present in the
molecular architecture of the transfection lipid [17].
With a view to introduce a more biodegradable link-
er group, an ester functionality has been synthetically
incorporated in between the hydrophobic anchor and
the positively charged nitrogen atoms in lipids 7^11
(Chart 1) using a two-carbon spacer unit.
Transfection e⁄ciencies of these lipids 7^11 were
tested in COS-1 and NIH3T3 cells using the pCMV-
L-Gal reporter gene across the lipid/DNA charge ra-
tios range 0.1^9 using cholesterol (in 1:1 mole ratio
with respect to the cationic lipid) as the colipid. Once
again, striking C-14 anchor dependency was ob-
served in both COS-1 and NIH3T3 cells (Fig.
2A,B). The lipids 7^9 and 11 did not show any trans-
fection in both COS-1 and NIH3T3 cells whereas
lipid 10 showed higher transfection e⁄ciency to lipo-
fectamine in NIH3T3 cells and somewhat less than
Fig. 2. Transfection e⁄ciencies of lipids 7^11 in COS-1 cells (A) and in NIH3T3 cells (B) using cholesterol as the colipid (at 1:1 mole
ratio of lipid to cholesterol). The transfection e⁄ciencies of the lipids 7 (a), 8 (b), 9 (E), 10 (F) and 11 (O) were compared with that
of lipofectamine (R). Experimental details are described in Fig. 1.
BBAMEM 78201 29-1-02
G. Venkata Srilakshmi et al. / Biochimica et Biophysica Acta 1559 (2002) 87^9592
lipofectamine in COS-1 cells (Fig. 2A,B). The opti-
mal lipid to DNA charge ratio for lipid 10 was ob-
served to be 1:1 in both COS-1 and NIH3T3 cells
(Fig. 2A,B). As in the case of lipid 4 mentioned
above, whether or not the signi¢cant transfection
property of lipid 10 has any relationship with the
e⁄cient cellular uptake of the relevant lipoplexes
cannot be ascertained from our present ¢ndings. Po-
tential biodegradability and comparable transfection
e⁄ciency to lipofectamine in both COS-1 and
NIH3T3 cells, makes lipid 10 a promising cationic
lipid.
3.3. Lipid^DNA interactions
Intercalation-induced £uorescence increase and
competition with cationic lipids to bind to DNA
has made EtBr an excellent tool to study cationic
lipid^DNA interactions. To assess the representative
lipid^DNA interactions of the presently described
mono-hydroxyethyl head group containing transfec-
tion lipids, we have titrated the EtBr:pCMV L-gal
complex with increasing amounts of cationic lipids
1^6. The data in Fig. 3 shows that lipids 1^3 interact
poorly with DNA as seen by their relatively poor
ability to exclude ethidium bromide from DNA. Lip-
ids 4^6 interact with DNA equally well (Fig. 3)
though lipid 4 is marginally weaker than the other
two. The decrease in EtBr £uorescence at charge ra-
tios of 3:1 was greater than 80% with lipids 4^6, and
greater than 30% with lipid 3, whereas there was no
signi¢cant decrease in £orescence with lipids 1 and 2.
Given their shorter hydrophobic anchor lengths, lip-
ids 1^3 may not form stable lipoplexes that are re-
quired for uptake of DNA by the cells. DNA that is
not present in a lipid complex either may get de-
graded by the serum proteins and/or may enter into
a non-productive pathway.
3.4. Toxicity assay
An MTT-based viability assay was performed to
assess the cytotoxicity of the six lipid formulations
(1^6) at various charge ratios with COS-1 cells. Lip-
ids 3 and 6 showed least cytotoxicity even at a 9:1
lipid/DNA charge ratio (Fig. 4). For lipids 1, 4 and 5
at a 3:1 charge ratio the toxicity varied from 15^25%
Fig. 3. EtBr exclusion from lipid^DNA complex. Decrease in
£uorescence of EtBr was used to assess the interaction of DNA
with lipids 1^6. DNA:EtBr complex was titrated with increas-
ing amounts of lipid. The order of addition of lipid or EtBr to
DNA did not alter the observed pro¢les. Fluorescence in the
absence of lipid was taken to be 100. The data presented are
an average of two independent experiments (n = 2).
Fig. 4. Cytotoxicity (viability) of lipids 1^6 on COS-1 cells.
Toxicities were assessed in COS-1 cells using MTT assay. The
absorption obtained with reduced formazon with cells in the
absence of lipids was taken to be 100. The data presented are
an average of three independent experiments (n = 3). Lipids:
1 (a), 2 (b), 3 (E), 4 (F), 5 (O), 6 (R).
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of the treated cells. Lipid 2 at a 3:1 charge ratio
showed the highest toxicity with 40% of the treated
cells being a¡ected. The toxicity of lipid 2 (with
shorter alkyl chains) may originate from its probable
detergent-like cell-lysing activity. The MTT based
viability assay was also performed to assess the cy-
totoxicity of the ¢ve lipid formulations (7^11) at var-
ious charge ratios with COS-1 cells. The lipid^DNA
complexation and treatment were identical to the
transfections (vide supra). Lipids 8^11 showed low
cytotoxicity even at a 9:1 charge ratio (Fig. 5). For
lipids 7^11 at a 3:1 charge ratio, the toxicity varied
from 10^20% of the treated cells being a¡ected. Lipid
7 at a 3:1 charge ratio showed the highest toxicity
with 25% of the treated cells being a¡ected. The tox-
icity of lipid 7 with its shorter alkyl chains may, like
lipid 2, originate from its probable detergent-like
cell-lysing activity.
In summary, the transfection e⁄ciencies of the C-
14 and C-16 analogs of DOMHAC (lipids 4 and 5,
respectively, Chart 1) were found to be remarkably
e⁄cient in transfecting COS-1 cells (comparable to
lipofectamine). Additionally, the present anchor-de-
pendency investigation also revealed that the C-14
analog of DOHEMAB (lipid 10, Chart 1) is signi¢-
cantly e⁄cient in transfecting COS-1 and NIH3T3
cells. To conclude, the anchor-dependence investiga-
tions delineated in this study convincingly demon-
strate that non-glycerol based cationic lipids contain-
ing a single hydroxyethyl head group and
hydrophobic C-14 or C-16 anchors are promising
non-toxic cationic transfection lipids for future use
in non-viral gene therapy.
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